Latest News and Press Releases

VANCOUVER, British Columbia and CAMBRIDGE, Mass., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN), a biopharmaceutical company dedicated to developing new standards of...

Out-licensing of commercialization rights allows for significant operating expense savingsUpfront payments improve near-term liquidity VANCOUVER, British Columbia, Feb. 06, 2019 (GLOBE NEWSWIRE) --...

Novelion General Counsel Benjamin Harshbarger Appointed as Interim Chief Executive Officer (CEO) VANCOUVER, British Columbia, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics...

VANCOUVER, British Columbia, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN), a biopharmaceutical company dedicated to developing and commercializing therapies for...

- New Aegerion loan facility, provided by existing bondholders, strengthens balance sheet and is expected to provide bridge to a potential comprehensive long-term capital restructuring - Company...

VANCOUVER, British Columbia and CAMBRIDGE, Mass., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN), a biopharmaceutical company dedicated to developing new standards of...

VANCOUVER, British Columbia, Aug. 23, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals...

VANCOUVER, British Columbia, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN), a biopharmaceutical company dedicated to developing and commercializing therapies for...

VANCOUVER, British Columbia, July 31, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to delivering new standards of care for people living...

VANCOUVER, British Columbia, July 03, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN) today announced that Mark Corrigan, M.D. has been appointed as Executive Chair of the Board of...